Amneal Pharmaceuticals (NASDAQ:AMRX) Price Target Raised to $10.00

Amneal Pharmaceuticals (NASDAQ:AMRX) had its price target lifted by Truist Financial from $9.00 to $10.00 in a report issued on Monday, Benzinga reports. They currently have a buy rating on the stock.

Separately, The Goldman Sachs Group boosted their price target on shares of Amneal Pharmaceuticals from $6.25 to $8.00 and gave the company a buy rating in a research report on Monday, May 6th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of Buy and a consensus price target of $9.00.

Amneal Pharmaceuticals Price Performance

Shares of NASDAQ AMRX opened at $7.91 on Monday. Amneal Pharmaceuticals has a 1 year low of $3.36 and a 1 year high of $8.15. The company has a debt-to-equity ratio of 121.31, a current ratio of 1.65 and a quick ratio of 0.97. The company’s 50-day moving average is $7.06 and its 200 day moving average is $6.35. The stock has a market capitalization of $2.44 billion, a P/E ratio of -14.13 and a beta of 1.23.

Hedge Funds Weigh In On Amneal Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of AMRX. Rothschild Investment LLC purchased a new stake in Amneal Pharmaceuticals during the 2nd quarter valued at about $26,000. DekaBank Deutsche Girozentrale bought a new position in shares of Amneal Pharmaceuticals in the second quarter worth approximately $42,000. nVerses Capital LLC purchased a new stake in shares of Amneal Pharmaceuticals during the second quarter valued at approximately $62,000. Atlanta Consulting Group Advisors LLC bought a new stake in shares of Amneal Pharmaceuticals during the first quarter valued at approximately $61,000. Finally, Xponance Inc. bought a new stake in shares of Amneal Pharmaceuticals during the second quarter valued at approximately $65,000. 31.82% of the stock is currently owned by institutional investors.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.